Opioid Safety: US FDA Hears Mixed Messages On Adding Posmarketing Studies To Labeling

Some advisory committee members said adding quantitative data on misuse, abuse, opioid use disorder and overdose to labeling would be helpful, but others worried the two epidemiological studies were not sufficiently generalizable to a broader population.